GRTS - Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
2024-04-07 00:22:19 ET
Summary
- Gritstone bio's GRANITE program shows promising preliminary results in the treatment of metastatic microsatellite stable colorectal cancer (MSS-CRC).
- The data suggests that GRANITE could be an innovative treatment for MSS-CRC and potentially other oncology indications.
- Gritstone bio's potential success in the CRC market could lead to significant revenue growth and establish its platform technology.
In my previous Gritstone bio ( GRTS ) article , I discussed how the company’s technology could make it a cutting-edge infectious disease firm with a strong list of collaborations that could rival Moderna ( MRNA ) and BioNTech ( BNTX ). However, I also noted that the company's biggest upside potential was its oncology programs, notably GRANITE, which could transform cancer treatment by targeting neoantigens, with encouraging early-stage results. Despite the upside potential, I also pointed out that Gritstone faces risks from clinical development, competition, and its cash position. As a result, I stressed that investors should exercise caution as the company approaches some of the upcoming data releases and the looming risk of an offering. Well, Gritstone recently publicized preliminary data from the ongoing Phase II portion of its Phase II/III GRANITE study evaluating a personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC). Then, the company followed the data release with an offering , decreasing the share price by more than 50%. Although the data was early, I believe there is enough data to show that their vaccine could be an innovative treatment for MSS-CRC and the same approach could be operative in other oncology indications....
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering